Crossmark

Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning

Published Online: 2024-05-17

Published Print: 2024-10

Authors

Massari, Francesco https://orcid.org/0000-0001-6476-6871
Rosellini, Matteo https://orcid.org/0000-0002-4920-9951
Mollica, Veronica
License Information

Text and Data Mining valid from 2024-05-17

Version of Record valid from 2024-05-17
More Information

Article History

First Online: 17 May 2024

Competing interests

: F.M. has received research support and/or honoraria from Astellas, BMS, Janssen, Ipsen, MSD and Pfizer outside the submitted work. The other authors declare no competing interests.

Document is current